Feature | April 08, 2011| Dave Fornell

Biocompatible Polymer Reduces Lesion Failure, Thrombosis Compared to Endeavor

April 9, 2011 - The Resolute zotarolimus-eluting stent using a new biocompatible polymer achieved a lower rate of restenosis and in-stent thrombosis compared to the Endeavor stent at 12 months in a U.S. trial. Data from the RESOLUTE U.S. trial was presented this week at the American College of Cardiology (ACC) Scientific Session in New Orleans.

Out of 1,112 patients who received the Resolute stent, only two cases of stent thrombosis were reported.

“This is one of the lowest stent thrombosis rates we have ever seen in a drug-eluting stent trial,” said Martin Leon, M.D., associate director of the Center for Interventional Vascular Therapy and professor of medicine at Columbia University/New York Presbyterian Hospital.

The Resolute stent’s rate of target lesion failure (TLF) at 12 months was 3.7 percent, compared with 6.5 percent for the historical control patients who received the Endeavor stent.

I think Resolute would be the preferred choice,” Leon said, based on the one-year data. “But, we don’t have the long-term follow-up as we do with the Endeavor. However, I feel most patients would be getting the Resolute stent."

The trial met its primary endpoint of non-inferiority to the historical control, the U.S. Food and Drug Administration (FDA)-approved Endeavor stent. It is the first U.S. study to observe the effect of drug elution characteristics on clinical outcomes. Both the Endeavor and Resolute stents are designed with the same cobalt chromium platform and use the same drug (zotarolimus), but the Resolute uses a new biocompatible polymer that allows for an extended drug release across approximately six months (compared to a 14-day release with Endeavor). This extended release is hypothesized to better prevent vessel renarrowing while still maintaining low stent thrombosis rates.

“The Resolute drug-eluting stent was shown in this study to deliver strong efficacy without a trade-off in safety through one year of patient follow-up,” Leon said. “The clinical results achieved with this new device show the important role that biocompatible polymers play in the design of drug-eluting stents.”

Study Details

Enrolling 1,402 patients across 116 U.S. investigational centers between August 2008 and December 2009, the research team conducted four analyses. The main study included 1,112 patients who received Resolute stents that were 2.5-3.5 mm in diameter. The primary endpoint for this group was 12-month target lesion failure (TLF – which combines the composite of cardiac death, target-vessel heart attack and clinically-driven target lesion revascularization). Clinical follow-up was performed at 30 days, six months, nine months and 12 months; it will continue at 18 months and annually thereafter through five years post-procedure.

The researchers compared the data from this main study group with historical data pulled from clinical trials of the Endeavor stent. In order to make accurate comparisons, the team used similar inclusion characteristics, data collection methodologies, endpoint definitions and statistical analyses. They used propensity score method to adjust for baseline covariates.

After conducting this analysis, the research team found that the Resolute stent’s rate of TLF at 12 months was 3.7 percent, compared with 6.5 percent for the historical control patients who received the Endeavor stent, meeting the study’s pre-set margin of non-inferiority (rate difference equals -2.8 percent, upper one-sided 95 percent confidence interval -1.3 percent, p

After looking at the individual components of the primary endpoint, the team found that the Resolute stent also had lower rates of target lesion revascularization, cardiac death and target-vessel heart attack, at 2 percent, 0.4 percent and 1.3 percent, respectively (compared to 4 percent, 0.8 percent and 2.4 percent for Endeavor).

Evaluation of the entire 1,402-person study group (which included patients with one or two lesions who received stents ranging from 2.25 mm to 4 mm) also showed strong outcomes for the Resolute stent, including a 4.7 percent rate of target-lesion failure and a 0.1 percent of definite or probable stent thrombosis. The overall population included 34 percent diabetic patients, the highest to date in any of the Resolute trials.

“The outcomes achieved in the diabetic group are better than expected and we can postulate that the Resolute’s prolonged drug elution profile may contribute to these favorable outcomes in this high-risk group,” Leon said.

Although the study was not a randomized trial, the researchers noted that the propensity score method did allow the team to adequately estimate the effect of changing one of the stent’s three components.

The study was funded by Medtronic. Leon serves on the scientific advisory board for Medtronic.

This study was published online this week in the Journal of the American College of Cardiology (JACC) and will appear in the April 26, 2011, print edition.

Related Content

BioSig Technologies, research agreement, UCLA, Pure EP System, EP lab, ventricular tachycardia model, VT
Technology | EP Lab| August 20, 2015
BioSig Technologies announced it has signed a sponsored research agreement with the regents of the University of...
Sunshine Heart, COUNTER HF pivotal study, resumes enrollment, C-Pulse, FDA
News | Heart Failure| August 18, 2015
Sunshine Heart Inc. announced an update in late July on its COUNTER HF U.S. pivotal study for the C-Pulse Heart Assist...
Biotronik, BioCONTINUE study, CRT-D, defibrillator, cardiac resynchronization therapy device, heart failure, first replacement
News | Cardiac Resynchronization Therapy Devices (CRT)| August 17, 2015
Biotronik announced that the first patient has been enrolled in the BioCONTINUE clinical trial (BIOtronik study to...
Medtronic, Endurant Evo AAA, stent graft system, first European cases
News | Stent Grafts| August 13, 2015
Medtronic plc announced that the first two European patient cases with the Endurant Evo AAA stent graft system were...
zebrafish, iWorx Systems Inc., ZS-200 Zebrafish ECG System, cardiac research
Technology | ECG| August 13, 2015
iWorx Systems Inc., developer of advanced physiology teaching and research instruments and software, has introduced a...
HeartWare, ENDURANCE2 trial, destination therapy, HVAS, HeartWare Ventricular Assist System
News | Ventricular Assist Devices (VAD)| August 11, 2015
HeartWare International Inc. announced that enrollment in the ENDURANCE2 destination therapy clinical trial has been...
ACC, Boehringer Ingelheim, Diabetes Collaborative Registry, American College of Cardiology
News | Cardiac Diagnostics| August 07, 2015
The American College of Cardiology (ACC) has announced that Boehringer Ingelheim is the newest industry sponsor of The...
Mayo Clinic, LVAD, study, heart failure, restrictive cardiomyopathy, RCM

Thoratec HeartMate II image courtesy of Thoratec

News | Ventricular Assist Devices (VAD)| August 07, 2015
Mayo Clinic is announcing results of a study on the effectiveness of left-ventricular assist devices (LVAD) in treating...
Boehringer Ingelheim, RE-DUAL PCI, RE-CIRCUIT, Pradaxa, first U.S. patients,
News | Antiplatelet and Anticoagulation Therapies| August 05, 2015
August 5, 2015 — Boehringer Ingelheim announced the first U.S.
triple therapy, dual antiplatelet therapy, atrial fibrillation, heart attack, older patients, JACC
News | Antiplatelet and Anticoagulation Therapies| August 04, 2015
Triple therapy is no better than dual antiplatelet therapy in preventing major adverse cardiac events in older patients...
Overlay Init